0001104659-22-012881.txt : 20220207 0001104659-22-012881.hdr.sgml : 20220207 20220207172853 ACCESSION NUMBER: 0001104659-22-012881 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220207 DATE AS OF CHANGE: 20220207 EFFECTIVENESS DATE: 20220207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TITAN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000910267 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943171940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-432660 FILM NUMBER: 22598575 BUSINESS ADDRESS: STREET 1: 400 OYSTER POINT BLVD STREET 2: SUITE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6502444990 MAIL ADDRESS: STREET 1: 400 OYSTER POINT BLVD STREET 2: SUITE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 D 1 primary_doc.xml X0708 D LIVE 0000910267 TITAN PHARMACEUTICALS INC 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA CALIFORNIA 94080 6502444990 DELAWARE None None Corporation true Marc Rubin 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA CALIFORNIA 94080 Executive Officer Director Executive Chairman Katherine Beebe DeVarney 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA CALIFORNIA 94080 Executive Officer Director Joseph A. Akers 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA CALIFORNIA 94080 Director M. David McFarlane 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA CALIFORNIA 94080 Director James R. McNab, Jr. 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA CALIFORNIA 94080 Director Pharmaceuticals Decline to Disclose 06b false 2022-02-04 false true true false 0 Maxim Group LLC 120708 None None 300 PARK AVE 16TH FLOOR NEW YORK NY NEW YORK 10022 NY NEW YORK false 7019570 1520669 5498901 Offering amount represents 1,289,796 Pre-Funded Warrants and 4,664,038 Placement Warrants at a combined purchase price of $1.179 per warrant. Amount sold represents 1,289,796 Pre-Funded warrants. false 1 106447 0 0 false TITAN PHARMACEUTICALS INC /s/ Kate Beebe DeVarney, Ph.D. Kate Beebe DeVarney, Ph.D. President and COO 2022-02-07